Acadia Pharmaceuticals Inc
ACAD
ISIN US0042251084 / Valor 1184425
Acadia Pharmaceuticals Inc
UMushroom community rating:
About company
Acadia Pharmaceuticals Inc is a healthcare company that has been a leader in providing essential solutions for individuals with specific medical conditions for over three decades. The company is known for pioneering the first and only approved therapies for hallucinations and delusions in Parkinson’s disease psychosis and Rett syndrome. Acadia's current clinical-stage developments are focused on addressing Prader-Willi syndrome, Alzheimer’s disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (20.08.2024):
Revenue Growth
Acadia Pharmaceuticals Inc. reported total net product sales of $242.0 million for the second quarter of 2024, marking a 46% increase year-over-year. This growth was driven by an 11% year-over-year increase in NUPLAZID net sales and an 11% sequential growth in DAYBUE net sales.
Research and Development Expenses
For the second quarter of 2024, Acadia Pharmaceuticals Inc. reported research and development expenses of $76.2 million, up from $58.8 million in the same period of 2023. The increase was primarily due to higher costs associated with ACP-101, ACP-204, and early-stage programs.
Selling, General and Administrative Expenses
Selling, general and administrative expenses for Acadia Pharmaceuticals Inc. were $117.1 million in the second quarter of 2024, compared to $96.0 million in the same quarter of 2023. The rise in expenses was mainly due to upfront costs related to a new consumer activation program and increased marketing costs to support DAYBUE.
Net Income
Acadia Pharmaceuticals Inc. reported a net income of $33.4 million, or $0.20 per common share, for the second quarter of 2024. This is a significant increase compared to the net income of $1.1 million, or $0.01 per common share, reported in the same period of 2023.
Cash and Investments
As of June 30, 2024, Acadia Pharmaceuticals Inc. had cash, cash equivalents, and investment securities totaling $500.9 million. This is an increase from $438.9 million at the end of December 31, 2023, indicating a strong financial position to support future growth.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
2697 M
Market cap (USD)
407,306
Daily traded volume (Shares)
16.725 / 16.08
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
